| Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or fever AF Zuppa, GB Hammer, JS Barrett, BF Kenney, N Kassir, S Mouksassi, ... The Journal of Pediatric Pharmacology and Therapeutics 16 (4), 246-261, 2011 | 73 | 2011 |
| Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma D Ouellet, N Kassir, J Chiu, MS Mouksassi, C Leonowens, D Cox, ... Cancer chemotherapy and pharmacology 77, 807-817, 2016 | 55 | 2016 |
| IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies LL Dupuis, C Sibbald, T Schechter, M Ansari, A Gassas, Y Théorêt, ... Biology of Blood and Marrow Transplantation 14 (5), 576-582, 2008 | 38 | 2008 |
| Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation T Nava, N Kassir, MA Rezgui, CRS Uppugunduri, P Huezo‐Diaz Curtis, ... British journal of clinical pharmacology 84 (7), 1494-1504, 2018 | 35 | 2018 |
| Population pharmacokinetics and B ayesian estimation of tacrolimus exposure in paediatric liver transplant recipients N Kassir, L Labbé, JR Delaloye, MS Mouksassi, AL Lapeyraque, ... British journal of clinical pharmacology 77 (6), 1051-1063, 2014 | 33 | 2014 |
| Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans JM Leeds, F Fenneteau, NH Gosselin, MS Mouksassi, N Kassir, JF Marier, ... Antimicrobial agents and chemotherapy 57 (3), 1136-1143, 2013 | 29 | 2013 |
| Population pharmacokinetics of intravenous linezolid in premature infants C Thibault, N Kassir, I Goyer, Y Théorêt, C Litalien, A Moussa, ... The Pediatric infectious disease journal 38 (1), 82-88, 2019 | 23 | 2019 |
| Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections J Autmizguine, KM Watt, Y Théorêt, N Kassir, C Laferrière, S Parent, ... The Pediatric infectious disease journal 32 (12), 1340-1344, 2013 | 23 | 2013 |
| Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: results from a multicenter population pharmacokinetic study K Ben Hassine, T Nava, Y Théoret, CE Nath, Y Daali, N Kassir, V Lewis, ... CPT: Pharmacometrics & Systems Pharmacology 10 (9), 1043-1056, 2021 | 22 | 2021 |
| Population pharmacokinetics and safety of piperacillin-tazobactam extended infusions in infants and children C Thibault, J Lavigne, C Litalien, N Kassir, Y Théorêt, J Autmizguine Antimicrobial agents and chemotherapy 63 (11), 10.1128/aac. 01260-19, 2019 | 22 | 2019 |
| Conversion from twice-to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study AL Lapeyraque, N Kassir, Y Théorêt, M Krajinovic, MJ Clermont, ... Pediatric Nephrology 29, 1081-1088, 2014 | 22 | 2014 |
| Limited sampling strategies for monitoring tacrolimus in pediatric liver transplant recipients JR Delaloye, N Kassir, AL Lapeyraque, F Alvarez, M Lallier, M Beaunoyer, ... Therapeutic drug monitoring 33 (4), 380-386, 2011 | 19 | 2011 |
| 643 RHB-104, a Fixed-Dose, Oral Antibiotic Combination Against Mycobacterium Avium Paratuberculosis (MAP) Infection, Is Effective in Moderately to Severely Active Crohn's Disease DY Graham, SA Naser, E Offman, N Kassir, R Hardi, T Welton, ... Official journal of the American College of Gastroenterology| ACG 114, S376-S377, 2019 | 18 | 2019 |
| Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia N Chen, N Kassir, A Laadem, AC Giuseppi, J Shetty, SE Maxwell, ... The Journal of Clinical Pharmacology 61 (1), 52-63, 2021 | 11 | 2021 |
| Pharmacokinetics, pharmacodynamics, and exposure‐response of lanadelumab for hereditary angioedema Y Wang, JF Marier, N Kassir, C Chang, P Martin Clinical and Translational Science 13 (6), 1208-1216, 2020 | 9 | 2020 |
| Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in … Y Wang, JF Marier, J Lavigne, N Kassir, P Martin The Journal of Clinical Pharmacology 60 (7), 903-914, 2020 | 9 | 2020 |
| The utility of a population approach in drug–drug interaction assessments: A simulation evaluation DD Wang, Y Yu, N Kassir, M Zhu, WD Hanley, JC Earp, AT Chow, ... The Journal of Clinical Pharmacology 57 (10), 1268-1278, 2017 | 8 | 2017 |
| Machine learning for exposure-response analysis: methodological considerations and confirmation of their importance via computational experimentations R Harun, E Yang, N Kassir, W Zhang, J Lu Pharmaceutics 15 (5), 1381, 2023 | 6 | 2023 |
| Population Pharmacokinetics and Exposure‐Response Analysis of nab‐Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors Y Li, N Kassir, N Chen, X Wang, M Palmisano, S Zhou Clinical Pharmacology in Drug Development 10 (2), 115-130, 2021 | 6 | 2021 |
| Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of … Y Li, N Kassir, X Wang, M Palmisano, S Zhou The Journal of Clinical Pharmacology 60 (8), 1061-1075, 2020 | 6 | 2020 |
